Tranzone secures GSK deal
Will store various products in Jebel Ali for distribution to the Gulf and Near East Region
The deal was signed during the opening ceremony for Tranzone’s new facility.
GSK will occupy a major part of Tranzone’s warehouse, contributing approximately 25% of revenue in 2012.
Tranzone said GSK had demanded top-of-the-range facilities and back up to protect products at all times and in all circumstances. Emphasis had also been placed on physical security such as access control and fire prevention and process quality.
Tranzone’s state-of-the-art 3PL warehouse at JAFZA in Jebel Ali provides storage, inventory management, as well as purchasing and re-invoicing to the distributor, all at one convenient location. The firm says it is able to store pharmaceuticals in an ideal environment, and its integrated system better links principals with distributors, removes layers of inefficiency and cuts costs while improving service quality.
You may also like
Trending Articles
You may also like
Finance
hVIVO’s CRS secures more than £5m in early-phase clinical trial contracts to strengthen 2026 pipeline
hVIVO’s German subsidiary CRS has signed more than £5 million in early-phase clinical trial contracts across cardiometabolic, dermatology, infectious disease, renal and oncology, bolstering its 2026 orderbook and highlighting the growing cross-selling benefits across the Group
Finance
Sofinnova Partners closes €650m ($750m) Capital XI fund to boost early-stage biotech investment across Europe and the US
Sofinnova Partners has closed its flagship Capital XI fund at €650m, surpassing its target. The Paris-based firm will use the fund to advance early-stage biotech and medtech companies in Europe and North America
Finance
Johnson & Johnson to acquire Halda Therapeutics for $3.05bn, expanding US oncology drug pipeline
Johnson & Johnson has agreed to acquire Connecticut-based Halda Therapeutics for $3.05bn. The deal strengthens its oncology portfolio, including Halda’s first-in-class RIPTAC therapy for advanced prostate cancer